Hims & Hers Health (HIMS) Projected to Post Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is expected to be announcing its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect the company to announce earnings of $0.09 per share and revenue of $578.9920 million for the quarter. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 3, 2025 at 5:00 PM ET.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm’s revenue for the quarter was up 72.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.06 earnings per share. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hims & Hers Health Stock Up 0.8%

Shares of HIMS opened at $48.86 on Monday. The company’s 50-day moving average price is $51.14 and its 200 day moving average price is $49.80. Hims & Hers Health has a 12-month low of $18.33 and a 12-month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The firm has a market cap of $11.04 billion, a P/E ratio of 61.07, a price-to-earnings-growth ratio of 3.38 and a beta of 2.25.

Insider Buying and Selling

In other news, insider Patrick Harrison Carroll sold 60,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Michael Chi sold 13,749 shares of the company’s stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $694,324.50. Following the sale, the insider owned 297,139 shares in the company, valued at $15,005,519.50. The trade was a 4.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,429,634 shares of company stock valued at $74,097,471. 17.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the 1st quarter valued at $30,000. EverSource Wealth Advisors LLC raised its stake in Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after buying an additional 687 shares in the last quarter. Palisade Capital Management LP acquired a new stake in Hims & Hers Health in the second quarter valued at $224,000. SkyView Investment Advisors LLC purchased a new stake in Hims & Hers Health during the 2nd quarter worth about $226,000. Finally, Meiji Yasuda Asset Management Co Ltd. acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth about $234,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on HIMS shares. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Truist Financial dropped their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Wall Street Zen cut Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Finally, KeyCorp assumed coverage on Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Reduce” and a consensus price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.